SecSonar.com

Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Corp. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Lexaria Bioscience Corp. (LEXX) is a Biotechnology company based in CA with a market capitalization of $12.2M. Revenue grew 52.0% year-over-year and free cash flow was negative at -$10.5M. This page tracks LEXX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CA · 7 employees · IPO Jan 12, 2021

Valuation

Valuation & price

$0.59 · as of May 17, 2026 · -61.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.07

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$1.46$0.99$0.53Jul 25Dec 25Jul 26Jul 7, 25$0.87Jul 9, 25$0.89Jul 11, 25$0.88Jul 15, 25$0.81Jul 17, 25$0.87Jul 21, 25$0.95Jul 23, 25$1.03Jul 25, 25$0.98Jul 29, 25$0.89Jul 31, 25$0.90Aug 4, 25$0.88Aug 6, 25$0.84Aug 11, 25$0.82Aug 13, 25$0.83Aug 15, 25$0.82Aug 19, 25$0.85Aug 21, 25$0.79Aug 25, 25$1.05Aug 27, 25$0.89Aug 29, 25$0.88Sep 3, 25$0.89Sep 5, 25$1.03Sep 9, 25$1.00Sep 11, 25$1.07Sep 16, 25$1.46Sep 18, 25$1.22Sep 22, 25$1.35Sep 24, 25$1.42Sep 26, 25$1.05Sep 30, 25$0.95Oct 2, 25$0.89Oct 6, 25$0.84Oct 8, 25$0.91Oct 10, 25$0.86Oct 14, 25$0.87Oct 16, 25$0.82Oct 21, 25$0.91Oct 23, 25$0.91Oct 27, 25$1.00Oct 29, 25$0.96Oct 31, 25$1.02Nov 4, 25$1.11Nov 6, 25$1.08Nov 10, 25$1.11Nov 12, 25$1.14Nov 14, 25$1.06Nov 18, 25$1.05Nov 20, 25$1.11Nov 25, 25$1.08Nov 28, 25$1.09Dec 2, 25$1.06Dec 4, 25$1.12Dec 8, 25$1.09Dec 10, 25$1.16Dec 12, 25$1.34Dec 16, 25$0.84Dec 18, 25$0.69Dec 22, 25$0.67Dec 24, 25$0.56Dec 29, 25$0.56Jan 2, 26$0.65Jan 6, 26$0.70Jan 8, 26$0.69Jan 12, 26$0.77Jan 14, 26$0.78Jan 16, 26$0.76Jan 21, 26$0.80Jan 23, 26$0.85Jan 27, 26$0.78Jan 29, 26$0.76Feb 2, 26$0.79Feb 4, 26$0.72Feb 9, 26$0.69Feb 11, 26$0.64Feb 13, 26$0.62Feb 18, 26$0.66Feb 20, 26$0.65Feb 24, 26$0.63Feb 26, 26$0.72Mar 2, 26$0.71Mar 4, 26$0.71Mar 6, 26$0.83Mar 10, 26$0.73Mar 12, 26$0.68Mar 17, 26$0.73Mar 19, 26$0.72Mar 23, 26$0.73Mar 25, 26$0.77Mar 27, 26$0.74Mar 31, 26$0.78Apr 2, 26$1.04Apr 7, 26$0.99Apr 9, 26$0.90Apr 13, 26$0.98Apr 15, 26$1.03Apr 17, 26$1.03Apr 22, 26$0.97Apr 24, 26$0.94Apr 28, 26$0.88Apr 30, 26$0.66May 4, 26$0.67May 6, 26$0.67May 8, 26$0.61May 12, 26$0.58May 14, 26$0.61May 18, 26$0.56May 20, 26$0.58May 22, 26$0.65May 28, 26$0.62Jun 1, 26$0.62Jun 3, 26$0.62Jun 5, 26$0.64Jun 9, 26$0.67Jun 11, 26$0.64Jun 15, 26$0.61Jun 17, 26$0.61Jun 22, 26$0.58Jun 24, 26$0.55Jun 26, 26$0.53Jul 2, 26$0.56
$0.5352-week range$1.53
Loading valuation history…

Fundamentals

Key fundamentals

$12.2M

Market cap

52.0%

Revenue growth (YoY)

99.6%

Gross margin

-$10.5M

Free cash flow (USD)

-$1.9M

Net debt

Net cash position

45.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$40.7KFY 2017$63.6KFY 2018$433.3KFY 2019$222.6KFY 2020$384.5KFY 2021$722.7KFY 2022$255.4KFY 2023$226.2KFY 2024$464.3KFY 2025$705.9K
$40.7K$705.9K

Free cash flow by year

2016 → 2025

FY 2016$-681.0KFY 2017$-1.6MFY 2018$-2.6MFY 2019$-3.8MFY 2020$-2.7MFY 2021$-4.1MFY 2022$-4.9MFY 2023$-6.1MFY 2024$-5.0MFY 2025$-10.5M
-$681K-$10.5M

Gross margin by year

2021 → 2025

FY 202175.7%FY 202271.9%FY 202386.1%FY 202499.0%FY 202599.6%
75.7%99.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Quarterly report10-Q FiledApr 13, 2026Filing

Questions

Frequently asked questions

What is Lexaria Bioscience Corp.'s market cap?

Lexaria Bioscience Corp. (LEXX) has a market capitalization of $12.2M.

What is LEXX's P/E ratio?

A meaningful P/E ratio is not available for LEXX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LEXX's price-to-book (P/B) ratio?

LEXX trades at 4.07 times book value per share.

Are insiders buying LEXX stock?

SEC Form 4 filings show no open-market insider buys at Lexaria Bioscience Corp. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

KPRX

Kiora Pharmaceuticals, Inc.

$11.9M

VYNE

VYNE Therapeutics Inc.

$11.4M

AIMD

Ainos, Inc.

$11.4M

HIND

Vyome Holdings, Inc.

$13M

LPCN

Lipocine Inc.

$13.2M

GDTC

CytoMed Therapeutics Limited

$13.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.